Rojas Juan I, Pappolla Agustín, Patrucco Liliana, Cristiano Edgardo, Miguez Jimena, Liwacki Susana, Tkachuk Verónica, Balbuena María E, Vrech Carlos, Deri Norma, Correale Jorge, Marrodan Mariano, Ysrraelit María C, Fiol Marcela, Leguizamon Felisa, Luetic Geraldine, Menichini María L, Lopez Pablo A, Pettinicchi Juan Pablo, Criniti Juan, Caride Alejandro, Tavolini Darío, Mainella Carolina, Zanga Gisela, Burgos Marcos, Hryb Javier, Barboza Andrés, Lazaro Luciana, Alonso Ricardo, Silva Berenice, Fernández Liguori Nora, Nadur Débora, Chercoff Aníbal, Martinez Alejandra, Steinberg Judith, Garcea Orlando, Carrá Adriana, Alonso Serena Marina, Carnero Contentti Edgar
Centro de Esclerosis Múltiple de Buenos Aires, CABA, Argentina.
Centro Universitario de Esclerosis Múltiple, Hospital Ramos Mejía, Buenos Aires, Argentina.
Neurol Sci. 2023 Jan;44(1):281-286. doi: 10.1007/s10072-022-06409-w. Epub 2022 Sep 27.
The objective was to evaluate time to reach an EDSS of 4, 6, and 7 in NMOSD and MOGAD patients included in the Argentinean MS and NMOSD registry (RelevarEM, NCT 03,375,177).
NMOSD patients diagnosed according to 2015 criteria and with MOGAD were identified. Patients with at least 3 years of follow-up and periodic clinical evaluations with EDSS outcomes were included. AQP4-antibody and MOG-antibody status was recorded, and patients were stratified as seropositive and seronegative for AQP4-antibody. EDSS of 4, 6, and 7 were defined as dependent variables. Log rank test was used to identify differences between groups.
Registry data was provided for a total of 137 patients. Of these, seventy-five presented AQP4-ab-positive NMOSD, 45 AQP4-ab-negative NMOSD, and 11 MOGAD. AQP4-ab status was determined by cell-based assay (CBA) in 72% of NMOSD patients. MOG-ab status was tested by CBA in all cases. Mean time to EDSS of 4 was 53.6 ± 24.5 vs. 63.1 ± 32.2 vs. 44.7 ± 32 months in seropositive, seronegative NMOSD, and MOGAD, respectively (p = 0.76). Mean time to EDSS of 6 was 79.2 ± 44.3 vs. 75.7 ± 48.6 vs. 54.7 ± 50 months in seropositive, seronegative NMOSD, and MOGAD (p = 0.23), while mean time to EDSS of 7 was 86.8 ± 54 vs. 80.4 ± 51 vs. 58.5 ± 47 months in seropositive, seronegative NMOSD, and MOGAD (p = 0.39).
No differences were observed between NMOSD (seropositive and seronegative) and MOGAD in survival curves.
目的是评估纳入阿根廷多发性硬化症和视神经脊髓炎谱系障碍登记处（RelevarEM，NCT 03375177）的视神经脊髓炎谱系障碍（NMOSD）和髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）患者达到扩展残疾状态量表（EDSS）4分、6分和7分的时间。
确定根据2015年标准诊断的NMOSD患者和MOGAD患者。纳入至少随访3年并进行定期临床评估且有EDSS结果的患者。记录水通道蛋白4（AQP4）抗体和MOG抗体状态，患者按AQP4抗体血清阳性和血清阴性分层。将EDSS 4分、6分和7分定义为因变量。采用对数秩检验确定组间差异。
共提供了137例患者的登记数据。其中，75例为AQP4抗体阳性的NMOSD，45例为AQP4抗体阴性的NMOSD，11例为MOGAD。72%的NMOSD患者通过基于细胞的检测（CBA）确定AQP4抗体状态。所有病例均通过CBA检测MOG抗体状态。血清阳性、血清阴性的NMOSD和MOGAD患者达到EDSS 4分的平均时间分别为53.6±24.5个月、63.1±32.2个月和44.7±32个月（p = 0.76）。血清阳性、血清阴性的NMOSD和MOGAD患者达到EDSS 6分的平均时间分别为79.2±44.3个月、75.7±48.个月和54.7±50个月（p = 0.23），而血清阳性、血清阴性的NMOSD和MOGAD患者达到EDSS 7分的平均时间分别为86.8±54个月、80.4±51个月和58.5±47个月（p = 0.39）。
在生存曲线方面，NMOSD（血清阳性和血清阴性）与MOGAD之间未观察到差异。
